Literature DB >> 8387357

Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells.

T A McCaffrey1, D J Falcone.   

Abstract

Previous studies have indicated that aged animals show an increased intimal hyperplasia after arterial injury. The present studies examined the hypothesis that the increased serum-free proliferation of aged smooth muscle cells (SMC), in vitro, was due to a loss of an antiproliferative signal, such as transforming growth factor-beta 1 (TGF-beta 1). Northern blot analysis of the mRNA derived from old (> 19 mo) or young (3-4 mo) rat aortic SMC indicated that both groups had an equivalent level of the 2.5 kB TGF-beta 1 message. Metabolic labeling with 35S-methionine and immunoprecipitation for TGF-beta 1 confirmed the de novo synthesis of TGF-beta 1 in rat SMC. Old and young SMC supernatants showed equal levels of active or latent (acid-activated) TGF-beta activity. Despite the similarities in the production of TGF-beta 1, old SMC were refractory to inhibition by TGF-beta 1, whereas young SMC were markedly inhibited (80%) by low levels of TGF-beta 1 (IC50 < 5 pg/ml). Binding studies at 4 degrees C indicated that old SMC exhibited reduced binding capacity for 125I-TGF-beta 1. Cross-linking studies confirmed that old SMC showed reduced binding of 125I-TGF-beta 1 to membrane sites corresponding to the high molecular weight type III receptor, as well as the 85-kDa type II and 65-kDa type I receptor. However, at 37 degrees C, old SMC degraded 125I-TGF-beta 1 more rapidly than young SMC. Combined, this data suggests that SMC derived from older animals are capable of normal production of TGF-beta 1 but fail to respond to the autocrine growth inhibitory effects of this agent, thereby leading to enhanced proliferation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387357      PMCID: PMC300929          DOI: 10.1091/mbc.4.3.315

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  32 in total

1.  Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase.

Authors:  H Y Lin; X F Wang; E Ng-Eaton; R A Weinberg; H F Lodish
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

Review 2.  Cell type and cell state specific antibodies in the analysis of early lesions of human atherosclerosis.

Authors:  A M Gown
Journal:  Am J Hypertens       Date:  1992-06       Impact factor: 2.689

3.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.

Authors:  F López-Casillas; S Cheifetz; J Doody; J L Andres; W S Lane; J Massagué
Journal:  Cell       Date:  1991-11-15       Impact factor: 41.582

4.  Latent forms of TGF-beta: structure and biology.

Authors:  K Miyazono; K Yuki; F Takaku; C Wernstedt; T Kanzaki; A Olofsson; U Hellman; C H Heldin
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 5.  Transforming growth factor-beta receptors and binding proteoglycans.

Authors:  F T Boyd; S Cheifetz; J Andres; M Laiho; J Massagué
Journal:  J Cell Sci Suppl       Date:  1990

6.  Concomitant loss of transforming growth factor (TGF)-beta receptor types I and II in TGF-beta-resistant cell mutants implicates both receptor types in signal transduction.

Authors:  M Laiho; M B Weis; J Massagué
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

7.  Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions.

Authors:  P C Dartsch; R Voisard; G Bauriedel; B Höfling; E Betz
Journal:  Arteriosclerosis       Date:  1990 Jan-Feb

8.  Inhibition of mink lung epithelial cell proliferation by transforming growth factor-beta is coupled through a pertussis-toxin-sensitive substrate.

Authors:  P H Howe; M R Cunningham; E B Leof
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

9.  Aging and atherosclerosis in the rabbit. 1. Distribution, prevalence and morphology of atherosclerotic lesions.

Authors:  L G Spagnoli; A Orlandi; A Mauriello; G Santeusanio; C de Angelis; R Lucreziotti; M T Ramacci
Journal:  Atherosclerosis       Date:  1991-07       Impact factor: 5.162

10.  Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasia.

Authors:  T A McCaffrey; D J Falcone; W Borth; C F Brayton; B B Weksler
Journal:  Biochem Biophys Res Commun       Date:  1992-04-30       Impact factor: 3.575

View more
  11 in total

Review 1.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 2.  The effects of ageing on cutaneous wound healing in mammals.

Authors:  G S Ashcroft; M A Horan; M W Ferguson
Journal:  J Anat       Date:  1995-08       Impact factor: 2.610

Review 3.  Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects.

Authors:  Ian Toma; Timothy A McCaffrey
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

Review 4.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

5.  Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.

Authors:  Wei Bin Fang; Iman Jokar; Anna Chytil; Harold L Moses; Ty Abel; Nikki Cheng
Journal:  Clin Exp Metastasis       Date:  2011-03-04       Impact factor: 5.150

6.  Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells.

Authors:  T A McCaffrey; B Du; S Consigli; P Szabo; P J Bray; L Hartner; B B Weksler; T A Sanborn; G Bergman; H L Bush
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.

Authors:  T A McCaffrey; S Consigli; B Du; D J Falcone; T A Sanborn; A M Spokojny; H L Bush
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 8.  A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis.

Authors:  Peter M van der Kraan; Esmeralda N Blaney Davidson; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2010-01-29       Impact factor: 5.156

Review 9.  Transforming growth factor-beta and breast cancer: Mammary gland development.

Authors:  M H Barcellos-Hoff; K B Ewan
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

10.  TGF-beta1 does not induce senescence of multipotent mesenchymal stromal cells and has similar effects in early and late passages.

Authors:  Gudrun Walenda; Khalid Abnaof; Sylvia Joussen; Steffen Meurer; Hubert Smeets; Björn Rath; Kurt Hoffmann; Holger Fröhlich; Martin Zenke; Ralf Weiskirchen; Wolfgang Wagner
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.